Literature DB >> 12084257

Lasers for median lobe hyperplasia.

R Muschter1, A P Gilling.   

Abstract

Laser treatment encompases a variety of techniques using different laser wavelengths, application systems, and surgical techniques to achieve contrasting tissue effects such as incision, resection, vaporization, or coagulation. Many studies have proven the clinical efficacy of the various laser techniques for the treatment of benign prostatiuc hyperplasia, including randomized studies versus transurethral prostatectomy (TURP). Recently, long-term follow-up of up to 5 years has demonstrated the durability of the results, although in some of the studies, retreatment rates were higher than after TURP. Median lobes were never seen as a contraindication for treatment in the laser based procedures. Technically, laser treatment techniques such as side-firing transurethral coagulation, contact- and free-beam laser vaporization, interstitial laser coagulation, and the holmium laser-based resection and enucleation are fully suitable for treatment of median lobes. Surprisingly, no studies focussing specifically on laser treatment of median lobes have been published.

Entities:  

Mesh:

Year:  2001        PMID: 12084257     DOI: 10.1007/s11934-001-0069-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  43 in total

1.  Evaluation of interstitial diode laser therapy for treatment of benign prostatic hyperplasia.

Authors:  A J Costello; D K Agarwal; H R Crowe; W J Lynch
Journal:  Tech Urol       Date:  1999-12

2.  The use of the holmium laser in the treatment of benign prostatic hyperplasia.

Authors:  P J Gilling; C B Cass; M D Cresswell; A R Malcolm; M R Fraundorfer
Journal:  J Endourol       Date:  1996-10       Impact factor: 2.942

Review 3.  Interstitial laser therapy of benign prostatic hyperplasia.

Authors:  R Muschter; H Whitfield
Journal:  Eur Urol       Date:  1999-02       Impact factor: 20.096

4.  Laser prostatectomy. Long-term follow-up of 303 patients.

Authors:  B Chertin; E Z Moriel; I Hadas-Halperin; W Abu-Arafeh; S Lupa; M Zilberman; A Farkas
Journal:  Eur Urol       Date:  1999-04       Impact factor: 20.096

5.  Holmium laser enucleation of the prostate for glands larger than 100 g: an endourologic alternative to open prostatectomy.

Authors:  P J Gilling; K M Kennett; M R Fraundorfer
Journal:  J Endourol       Date:  2000-08       Impact factor: 2.942

6.  A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study.

Authors:  S Gujral; P Abrams; J L Donovan; D E Neal; S T Brookes; K N Chacko; M J Wright; A G Timoney; T J Peters
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

7.  A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study.

Authors:  J L Donovan; T J Peters; D E Neal; S T Brookes; S Gujral; K N Chacko; M Wright; L G Kennedy; P Abrams
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

8.  Low-power v high-power KTP laser: improved method of laser ablation of prostate.

Authors:  W B Shingleton; F Terrell; L Renfroe; J Kolski; J E Fowler
Journal:  J Endourol       Date:  1999-02       Impact factor: 2.942

9.  Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup.

Authors:  P J Gilling; M Mackey; M Cresswell; K Kennett; J N Kabalin; M R Fraundorfer
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

10.  Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience.

Authors:  P J Gilling; C B Cass; A R Malcolm; M R Fraundorfer
Journal:  J Endourol       Date:  1995-04       Impact factor: 2.942

View more
  1 in total

Review 1.  [Surgical and instrumental management of benign prostatic hyperplasia].

Authors:  R Muschter; O Reich
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.